Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the 3-microgram dose at least two months after the primary vaccine series at a time when the omicron variant was predominating, the company announced today. Pfizer expects to submit the data to the Food and Drug Administration this week for the company’s emergency use application.

Related News Articles

Headline
The Food & Drug Administration last week revised its Evusheld fact sheet for health care providers, recommending repeat dosing every six months if patients…
Headline
The departments of Health and Human Services and Defense yesterday announced an agreement to purchase at least 105 million doses of a Pfizer omicron-…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…